RU2011136111A - METHOD FOR SELECTING A THERAPY SCHEME FOR PATIENTS WITH ACTION DISEASE - Google Patents
METHOD FOR SELECTING A THERAPY SCHEME FOR PATIENTS WITH ACTION DISEASE Download PDFInfo
- Publication number
- RU2011136111A RU2011136111A RU2011136111/15A RU2011136111A RU2011136111A RU 2011136111 A RU2011136111 A RU 2011136111A RU 2011136111/15 A RU2011136111/15 A RU 2011136111/15A RU 2011136111 A RU2011136111 A RU 2011136111A RU 2011136111 A RU2011136111 A RU 2011136111A
- Authority
- RU
- Russia
- Prior art keywords
- dia
- treatment
- laser therapy
- endorphins
- cortisol
- Prior art date
Links
Landscapes
- Radiation-Therapy Devices (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Способ прогнозирования эффективности дополнительного включения лазеротерапии в схему лечения пациентов с угревой болезнью, заключающийся в использовании регрессионного уравнения: К=-8,03328-0,0710001·кортизол-0,334017·эндорфины+0,0526548·ЛГШП+1,31453·ДИА, где К- коэффициент эффективности динамики дерматологического индекса акне (ДИА), кортизол - уровень кортизола в плазме крови до начала лечения, эндорфины - уровень эндорфинов в плазме крови до начала лечения, ЛПНП - уровень липопротеинов низкой плотности в плазме крови до начала лечения, ДИА- значение индекса ДИА до начала лечения; если Ксоставляет 6,6 и менее, то дополнительное назначение лазеротерапии в комплексном лечении малоэффективно - не более 50% улучшения ДИА в процессе лечения; если Кболее 6,6, но менее 7,9, то назначение лазеротерапии средне эффективно - прогнозируют снижение индекса ДИА в процессе лечения от 50 до 75%; если Ксоставляет 7,9 и более, то дополнительное назначение лазеротерапии по прогнозу будет сопровождаться динамикой снижения ДИА в процессе лечения более чем на 75%.A method for predicting the effectiveness of the additional inclusion of laser therapy in the treatment scheme for patients with acne, which consists in using the regression equation: K = -8.03328-0.0710001 · cortisol-0.334017 · endorphins + 0.0526548 · LGSH + 1.31453 · DIA where K is the efficiency coefficient of the dynamics of the dermatological index of acne (DIA), cortisol is the level of cortisol in the blood plasma before treatment, endorphins is the level of endorphins in the blood plasma before treatment, LDL is the level of low density lipoproteins in the blood plasma before treatment, DIA - value in dex DIA before treatment; if X is 6.6 or less, then the additional purpose of laser therapy in complex treatment is ineffective - no more than 50% improvement in DIA during treatment; if more than 6.6, but less than 7.9, then the appointment of laser therapy is moderately effective - they predict a decrease in the DIA index during treatment from 50 to 75%; if X is 7.9 or more, then the additional appointment of laser therapy according to the forecast will be accompanied by a dynamics of a decrease in DIA in the course of treatment by more than 75%.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011136111/15A RU2499990C2 (en) | 2011-08-30 | 2011-08-30 | Method for choosing therapeutic regimen for patients suffering acne |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011136111/15A RU2499990C2 (en) | 2011-08-30 | 2011-08-30 | Method for choosing therapeutic regimen for patients suffering acne |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011136111A true RU2011136111A (en) | 2013-03-10 |
RU2499990C2 RU2499990C2 (en) | 2013-11-27 |
Family
ID=49123100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011136111/15A RU2499990C2 (en) | 2011-08-30 | 2011-08-30 | Method for choosing therapeutic regimen for patients suffering acne |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2499990C2 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2230554C2 (en) * | 2002-05-07 | 2004-06-20 | Глубокова Ирина Борисовна | Method for treating normo-atrophic scars with mechanic dermabrasion by applying combined collagen covering with antimicrobial preparation |
US20100003315A1 (en) * | 2008-07-02 | 2010-01-07 | Willeford Kenneth L | Method and Composition for the Treatment of Skin Conditions |
-
2011
- 2011-08-30 RU RU2011136111/15A patent/RU2499990C2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2499990C2 (en) | 2013-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2548508T3 (en) | Disease treatment methods | |
MX2014005996A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy. | |
BR112013030606A2 (en) | biomarkers for hedgehog inhibitor therapy | |
HK1202157A1 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment | |
UA116766C2 (en) | A Binding molecule that is biospecific to CCMA and CD3 | |
WO2012092364A3 (en) | Method for sympathetic rebalancing of patient | |
BR112014005427A2 (en) | method deployed by a computing device | |
BR112015031542A2 (en) | cancer patient reaction prediction methods, cancer treatment method, treatment reaction prediction kit and innovative processes, methods and uses | |
AR090040A1 (en) | METHODS AND KITS FOR THE FORECAST OF COLORRECTAL CANCER | |
EA201101568A1 (en) | TREATMENT OF EX VIVO IMMUNOLOGICAL DISORDERS THROUGH PKC-TETA INHIBITORS | |
MX365418B (en) | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies. | |
AR084234A1 (en) | PREDICTIVE METHODS AND METHODS TO TREAT ARTHRITIS USING INTERLEUQUINE ANTAGONISTS 17 (IL-17) | |
NZ630421A (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
UA118658C2 (en) | Diagnostic method for predicting response to tnf? inhibitor | |
EA201490614A1 (en) | TREATMENT OF DISEASES AND DISTURBANCES CAUSED BY ACTIVITY OF NF-kB TRANSCRIPTION FACTOR | |
WO2012145535A3 (en) | Animal model of human cancer and methods of use | |
EP2533788A4 (en) | Stable solution | |
MX358726B (en) | Predictive biomarker of survival in the treatment of renal cell carcinoma. | |
BR112014009310A2 (en) | lmp risk assessment methods and related apparatus | |
BR112015004653A2 (en) | cancer diagnostic and therapeutic method of target molecules expressed in cancer stem cells | |
RU2011136111A (en) | METHOD FOR SELECTING A THERAPY SCHEME FOR PATIENTS WITH ACTION DISEASE | |
RU2008150292A (en) | METHOD FOR PRODUCING THE TECHNETSIA-99m CHROMATOGRAPHIC GENERATOR FROM MOLYBDENE-98 IRRADIATED BY NEUTRONS | |
MX371426B (en) | Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment. | |
WO2012138740A3 (en) | Risk analysis for disease development | |
RU2011105150A (en) | METHOD FOR FORECASTING THE FORMATION OF VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS WITH |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20131027 |